News | September 29, 2014

Thoratec Announces Start Of Heartmate III U.S. Clinical Trial

heartmate III, tohratec, heart failure, heart failure treatment

HeartMate III

September 29, 2014 – Thoratec Corporation announced that it has begun to enroll patients in the HeartMate III U.S. clinical trial. 
 
"We are excited to continue our recent pipeline progress with the start of the U.S. clinical trial for HeartMate III," said Gary F. Burbach, President and Chief Executive Officer. "Our innovative U.S. trial design allows for the evaluation of patients for both short-term and long-term support, and we are particularly enthusiastic about the potential for HeartMate III to drive future growth of both the LVAD market and Thoratec," he added. 
 
HeartMate III is a centrifugal-flow chronic left ventricular assist system. The fully magnetically levitated technology foundation is designed to lower adverse event rates through improved hemocompatibility, while HeartMate III also enhances ease of surgical placement through a compact size. In addition to the current U.S. IDE trial, patient enrollment continues in the HeartMate III CE Mark clinical trial, which began in June. 
 
James Long M.D., Ph.D., Director of Integris Advanced Cardiac Care and Medical Director of the Nazih Zuhdi Transplant Institute at Integris Baptist Medical Center in Oklahoma City, Oklahoma performed the first HeartMate III implant in the U.S. Long and his team have a well-established history of innovation in mechanical circulatory support, including participation in clinical trials for every previous HeartMate technology. 
 
"We look forward to further enrollment in this important study for the field, and the opportunity to demonstrate the potential benefits of the unique fully magnetically levitated technology of HeartMate III," commented Long.
 
Additionally, Douglas Horstmanshof M.D., Co-Director of Integris Advanced Cardiac Care at Integris Baptist Medical Center added, "HeartMate III represents an exciting technology with the potential to advance the treatment of heart failure and improve quality of life for the large number of untreated patients that could benefit from chronic circulatory support." 
 
The HeartMate III U.S. clinical trial is a randomized non-inferiority study comparing HeartMate III with HeartMate II and includes a primary endpoint of survival free of device replacement and debilitating stroke. The trial began enrollment in a safety phase under conditional approval from the FDA for 30 patients at five sites. Enrollment will broaden to up to 60 sites following full approval from the FDA based on 30-day follow-up data from the initial safety phase. The first 294 randomized patients will be followed for six months to evaluate a short-term indication such as Bridge-to-Transplantation. The first 366 randomized patients will be followed for 24 months to evaluate a long-term indication such as Destination Therapy. The trial also allows for approximately 600 additional randomized patients to be enrolled beyond the pivotal cohort in order to assess secondary endpoints. 
 
For more information: www.thoratec.com.

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Overlay Init